Halozyme Therapeutics has signed a global partnership and licence agreement with Incyte to assess additional subcutaneous formulations of INCA033989 in patients with mutCALR-expressing MPNs.

Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn).

The JCA process does not have any influence over pricing and Ipsen must still navigate reimbursement access on a country-by-country basis. Credit: HJBC / Shutterstock.com. The first published joint ...

UK biotech financing recovery was present in the private markets in Q2 2026 as the sector contends with a tough global funding landscape.

Aptar Pharma has launched a collaborative system-level framework designed to support the development of injectable drug delivery systems.

The therapies’ availability will offer a route to personalised, mutation-specific approaches for types of rare blood cancers.

Novo Nordisk is continuing to maintain its advantage in the obesity pill race after winning European approval for oral Wegovy (semaglutide). The European Commission (EC) granted m ...

MSD (Merck & Co) has won US Food and Drug Administration (FDA) approval for its cholesterol-lowering pill, marking a significant milestone in the drugmaker’s push to reduce revenue reliance on ...

Harbour BioMed and Kelun-Biotech have received approval from China’s NMPA for their IND application for the HBM7575/SKB575 bispecific antibody intended to treat asthma.

The FDA has issued traditional approval to Novartis for Fabhalta to slow the decline of kidney function in adults with primary IgAN who are at risk of disease progression.

Cellares and Sonoma Biotherapeutics have partnered to automate the manufacturing of the latter’s SBT-77-7101 programme using the Cellares Cell Shuttle platform.

Blood-based biomarkers could play a key role in detecting and treating Alzheimer’s early at the first point of contact, experts say.